In this small phase I/II study, 20 patients with advanced cancers who were receiving chemotherapy also took a commercial beta-(1,3)(1,6)-D-glucan preparation containing additional IP6. Investigators monitored tolerability and blood-cell measures and reported that the regimen was generally tolerated, with signals that warranted further study. The trial was small, lacked a randomized control group, combined ingredients, and was not designed to prove tumor response or survival benefit; it does not directly evaluate an Aureobasidium product.
Twenty chemotherapy-treated patients received a commercial beta-glucan plus IP6 preparation.
The regimen appeared tolerable and exploratory blood-cell findings supported further research.
The small uncontrolled, multi-ingredient study cannot establish cancer efficacy or an Aureobasidium-specific effect.
AI-generated summary for accessibility. Always refer to the original paper.
Weitberg, Alan B. A phase I/II trial of beta-(1,3)/(1,6) D-glucan in the treatment of patients with advanced malignancies receiving chemotherapy. Journal of Experimental & Clinical Cancer Research. 2008. DOI: 10.1186/1756-9966-27-40.
For scientific reference only. Not medical advice. Consult a qualified healthcare professional. See our Medical Disclaimer.